Inositol (PCOS).

An epimerase converts myo-inositol to D-chiro-inositol, and the two isomers serve different arms of insulin second-messenger signalling. The 40 to 1 ratio used in formulation mirrors the ratio found in plasma.

Inositol acts as a second messenger downstream of the insulin receptor while metformin acts upstream through AMPK activation and hepatic glucose output. Both push normal glucose handling in the same direction by different levers, so effects can add.

Alpha lipoic acid supports glucose uptake through GLUT4 translocation and mitochondrial substrate handling, which sits beside rather than on top of the inositol phosphoglycan messenger route.

The insulin receptor is a magnesium-dependent tyrosine kinase, so magnesium status sets how strongly the receptor can signal at all. Inositol only carries a message the receptor has already generated.

Chromium is proposed to act through chromodulin, which amplifies insulin receptor kinase activity upstream of the inositol messenger. The two act at different points of one chain.

Berberine activates AMPK and shifts hepatic glucose handling, a separate lever from the inositol phosphoglycan second messenger.

NAC supplies cysteine for glutathione, and redox tone influences insulin receptor signalling independently of the inositol messenger pool.

Lithium inhibits inositol monophosphatase and so lowers the free inositol pool that this ingredient is intended to raise. The two pull in opposite directions on one recycling cycle.

Phytase hydrolyses dietary phytic acid, which is inositol hexaphosphate, into free inositol and phosphate. It raises the inositol available from food.

Myo-inositol products aimed at reproductive-age women are usually built alongside folic acid because folate intake before conception is a separate, well-established nutritional recommendation. The two act on different pathways and neither changes the other's absorption. Folic acid co-occurs with inositol across the literature for that formulation reason rather than because of a measured interaction. No combination trial is cited here.

A 2026 review groups vitamin D, myo-inositol and melatonin as a redox and endocrine trio studied together in reproductive-age women with irregular ovulatory cycles. Vitamin D status tracks with insulin signalling markers and myo-inositol feeds the inositol phosphoglycan arm of that same signalling, so the overlap is mechanistic. The review is a synthesis of mechanism, not a combination trial, so the pairing sits at review-level confidence.

Melatonin concentrates in follicular fluid and is discussed alongside myo-inositol as a follicular antioxidant. Myo-inositol is itself abundant in follicular fluid as an osmolyte and signalling precursor, so the two are described as complementary rather than interchangeable. The supporting material is a mechanistic review plus a melatonin-only meta-analysis in assisted reproduction; direct combination outcome data is not cited here.

A 2024 Nutrients study evaluated a food supplement combining glucomannan, D-chiro-inositol and cinnamon. Glucomannan is a viscous fibre that slows gastric emptying and blunts the post-meal glucose rise, a different route to the same post-meal handling that inositol signalling touches. Because the product was tested as one fixed blend, the effect cannot be assigned to either component alone.

Cinnamon appeared with D-chiro-inositol and glucomannan in one tested blend. Cinnamon polyphenols are studied for post-meal glucose handling, which is the same functional area inositol signalling sits in, so the pairing is coherent. The blend design means the contribution of cinnamon on its own was not isolated.

CoQ10 sits in the mitochondrial electron transport chain and is commonly formulated with myo-inositol in products aimed at oocyte quality. Myo-inositol works on membrane signalling and osmotic balance rather than on the respiratory chain, so the two do not overlap. No trial cited here tested the pair against either alone.

Selenium is a cofactor for glutathione peroxidases, which is why antioxidant-oriented inositol blends often carry it. The rationale is enzymatic antioxidant support running alongside inositol's signalling role, two separate mechanisms in the same formulation. This is formulation logic and mechanism, not a measured combination result.

Zinc is a structural and catalytic cofactor across hundreds of enzymes, including superoxide dismutase, and turns up in antioxidant-oriented inositol blends. There is no shared transport route with inositol and no absorption interaction to flag. The pairing rests on formulation practice rather than on combination data.

Myo-inositol is the head group of phosphatidylinositol and EPA and DHA occupy the fatty acyl positions of membrane phospholipids, so the two contribute to different parts of the same molecule class. That is a structural relationship rather than a demonstrated functional one. No combination outcome study is cited for this pair.

L-carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation, a metabolic route separate from inositol signalling. The two appear together in blends aimed at oocyte and sperm energetics. Read the pairing as mechanistic rationale, not as a measured combination effect.

Creatine enters cells on SLC6A8 and myo-inositol on the sodium-coupled SMIT transporters, so both are sodium-dependent osmolyte-class systems but they are different proteins. There is no established competition between them at supplement doses. Creatine co-occurs with inositol in the literature largely because both are cellular osmolytes, which is a shared category rather than a shared route.

Alpha-tocopherol terminates lipid peroxidation chains inside membranes, the same membranes whose inositol-containing phospholipids carry signalling function. The relationship is positional rather than reactive; vitamin E does not alter inositol uptake. No combination study is cited here.